The management of acute chest pain remains a significant challenge in clinical practice, given its broad differential diagnosis and potential for severe outcomes. This article provides an overview of a comprehensive approach to evaluating and managing acute chest pain in the clinical setting.
Firstly, a thorough history and physical examination are crucial. The nature, location, duration, and radiation of pain, associated symptoms, and risk factors for cardiovascular disease should be elicited. Physical examination should focus on vital signs, cardiac and respiratory examinations, and signs of peripheral vascular disease.
Diagnostic testing should be guided by the pretest probability of disease. Electrocardiogram (ECG) and cardiac biomarkers are the first-line investigations. Further testing like stress testing, coronary computed tomography angiography (CCTA), or invasive coronary angiography may be indicated based on initial results and patient characteristics.
Risk stratification is essential to guide management. Multiple risk scores are available, including the HEART score and the GRACE score. These scores incorporate clinical, ECG, and biomarker findings to predict the risk of adverse outcomes and guide decision-making regarding hospitalization and further testing.
Management should be tailored to the underlying cause of chest pain and the patient's risk profile. This may range from reassurance and outpatient follow-up for low-risk patients to urgent revascularization for patients with acute coronary syndromes. All patients should receive education about warning signs and when to seek immediate medical attention.
In conclusion, a systematic approach to acute chest pain, including thorough initial evaluation, appropriate diagnostic testing, risk stratification, and patient-centered management, can help clinicians navigate this complex clinical scenario. Ongoing research and evolving guidelines will continue to refine our approach to this common, yet challenging, clinical problem.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation